S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Amylyx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMLX)

$14.16
+0.58 (+4.27%)
(As of 11/30/2023 ET)
Compare
Today's Range
$13.44
$14.37
50-Day Range
$12.07
$18.81
52-Week Range
$11.82
$41.93
Volume
1.38 million shs
Average Volume
1.16 million shs
Market Capitalization
$956.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
224.9% Upside
$46.00 Price Target
Short Interest
Healthy
14.19% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.64mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
105.88%
From $0.85 to $1.75 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

79th out of 949 stocks

Pharmaceutical Preparations Industry

25th out of 437 stocks


AMLX stock logo

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Stock Price History

AMLX Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals Inc AMLX
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/11/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
374
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.00
High Stock Price Target
$50.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+224.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-198,380,000.00
Pretax Margin
1.94%

Debt

Sales & Book Value

Annual Sales
$294.22 million
Book Value
$6.20 per share

Miscellaneous

Free Float
59,551,000
Market Cap
$956.05 million
Optionable
Not Optionable
Beta
-0.68
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 56)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 52)
    Chief Legal Officer & General Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 64)
    Global Head of Human Resources & CHRO
  • Ms. Margaret M. Olinger M.B.A (Age 58)
    Global Head of Commercial & Chief Commercial Officer
    Comp: $567k
  • Dr. Patrick D. Yeramian M.D. (Age 64)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer
    Comp: $497.84k














AMLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price target for 2024?

5 equities research analysts have issued 12-month price objectives for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $40.00 to $50.00. On average, they anticipate the company's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2023?

Amylyx Pharmaceuticals' stock was trading at $36.95 on January 1st, 2023. Since then, AMLX stock has decreased by 61.7% and is now trading at $14.16.
View the best growth stocks for 2023 here
.

Are investors shorting Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 7,070,000 shares, a decrease of 10.8% from the October 31st total of 7,930,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.2% of the company's shares are sold short.
View Amylyx Pharmaceuticals' Short Interest
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Monday, March, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The company earned $21.89 million during the quarter, compared to analysts' expectations of $3.05 million. Amylyx Pharmaceuticals had a net margin of 0.62% and a trailing twelve-month return on equity of 0.49%.

Is Amylyx Pharmaceuticals a good dividend stock?

Amylyx Pharmaceuticals (NASDAQ:AMLX) pays an annual dividend of $1.02 per share and currently has a dividend yield of 0.00%.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (3.73%), Avidity Partners Management LP (2.60%), Adage Capital Partners GP L.L.C. (2.52%), Morgan Stanley (1.41%), Emerald Advisers LLC (1.24%) and Emerald Mutual Fund Advisers Trust (1.01%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends
.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AMLX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -